FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain
Executive Summary
FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary
You may also be interested in...
FDA May Revisit Antidepressant “Black Box” Suicidality Warning
FDA will monitor emerging data on suicides and antidepressants as it becomes available to determine if an uptick in suicides among adolescents is associated with the decline in prescriptions for antidepressants that followed the addition of a "black box" warning to labeling for the products
FDA May Revisit Antidepressant “Black Box” Suicidality Warning
FDA will monitor emerging data on suicides and antidepressants as it becomes available to determine if an uptick in suicides among adolescents is associated with the decline in prescriptions for antidepressants that followed the addition of a "black box" warning to labeling for the products
Changes To Antidepressant Black Box On Suicide Recommended By FDA Panel
FDA's findings that the suicidality risk with antidepressants does not extend beyond young adults should be added to the current "black box" warning on pediatric suicidality, the Psychopharmacologic Drugs Advisory Committee says